ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

VENN Venn Life Sciences Holdings Plc

6.85
0.00 (0.00%)
22 Jul 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Venn Life Sciences Holdings Plc LSE:VENN London Ordinary Share GB00B9275X97 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 6.85 6.70 7.00 0.00 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Open Orphan PLC Rule 2.9 Announcement (2648W)

10/12/2019 7:01am

UK Regulatory


Venn Life Sciences (LSE:VENN)
Historical Stock Chart


From Jul 2019 to Jul 2024

Click Here for more Venn Life Sciences Charts.

TIDMORPH

RNS Number : 2648W

Open Orphan PLC

10 December 2019

Open Orphan plc

("Open Orphan or the "Company")

Rule 2.9 Announcement

In accordance with Rule 2.9 of the City Code on takeovers and Mergers, the Company confirms that, as at the close of business on 9 December 2019, being the last business day prior to the date of this announcement, it had 254,572,567 ordinary shares of 0.1 pence each in issue. The Company holds no ordinary shares in treasury. Accordingly, the total number of voting rights in Open Orphan is 254,572,567. The International Securities Identification Number ("ISIN") for Open Orphan's ordinary shares is GB00B9275X97.

For further information please contact:

Open Orphan plc +353 (0)1 644 0007

Cathal Friel, Chief Executive Officer

   Arden Partners plc (Nominated Adviser and Joint Broker)                    +44 (0)20 7614 5900 

John Llewellyn-Lloyd / Benjamin Cryer

   Davy (Euronext Growth Adviser and Joint Broker)                                +353 (0)1 679 6363 

Anthony Farrell

Camarco (Financial PR) +44 (0)20 3757 4980

Tom Huddart / Billy Clegg / Daniel Sherwen

Notes to Editors:

Open Orphan plc is a European-focussed, rare and orphan drug consulting services platform. The Company consists of four elements: a European clinical research organisation and consultancy; an orphan drug services business; a Virtual Rep and Data Access Platform consisting of physicians and key opinion leaders; and a Health Data Platform to partner with Patient Advocacy Groups. The Company is targeting rapid growth in one of the fastest growing sectors in the global pharmaceutical industry targeting under-supplied treatment for life threatening or very serious diseases and rare disorders.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

RTTBLBDDGUGBGCC

(END) Dow Jones Newswires

December 10, 2019 02:01 ET (07:01 GMT)

1 Year Venn Life Sciences Chart

1 Year Venn Life Sciences Chart

1 Month Venn Life Sciences Chart

1 Month Venn Life Sciences Chart

Your Recent History

Delayed Upgrade Clock